Dr. John Webb, MD
Claim this profileProvidence Health - St. Paul's Hospital
Studies Heart Valve Disease
Studies Aortic Valve Stenosis
4 reported clinical trials
9 drugs studied
Affiliated Hospitals
Clinical Trials John Webb, MD is currently running
Transcatheter Valve Repair
for Mitral Regurgitation
This trial tests a new device called Edwards PASCAL that fixes leaky heart valves without surgery. It is for patients who can't have surgery or haven't improved with other treatments. The device helps the valve close better, stopping blood from leaking backward.
Recruiting1 award N/A9 criteria
TAVI
for Heart Valve Disease
Transcatheter aortic valve implantation (TAVI) serves a growing spectrum of patients with symptomatic severe aortic stenosis (AS). Approximately 80% of surgical aortic valve replacements is performed using a bioprosthesis1. Durability of surgical bioprostheses varies based on the patient's age at the moment of implantation, type and size etc2. TAVI has become the preferred treatment for degenerated aortic bioprostheses in elderly patients3. The median time since index surgical aortic valve replacement (SAVR) and for bioprosthetic valve degeneration is typically 8 - 10 years4-6. TAVI in this setting has proven to have equally favorable results as in native aortic valves7. Balloon expandable8 and self-expanding9 transcatheter heart valves (THV) can be used in a degenerated bioprosthesis and each have specific assets and limitations. TAVI in a failed bioprosthesis can cause coronary obstruction, THV migration, paravalvular leakage and prosthesis patient mismatch. The SAPIEN-3 / Ultra and EVOLUT R/Pro are the 2 most commonly used THV platforms in contemporary clinical practice including treatment of failing surgical aortic bioprostheses. Objective: To compare TAVI with EVOLUT R/Pro vs. SAPIEN-3 / Ultra in terms of device success. Study design: International multi-center randomized study with 1:1 randomization to TAVI with SAPIEN-3 / Ultra or Evolut R/Pro. Study population: 440 patients with a failing surgical aortic bioprosthesis (aortic stenosis with or without aortic regurgitation) and selected for transfemoral TAVI by heart-team consensus. Investigational intervention: Transfemoral TAVI with SAPIEN-3 / Ultra or Evolut R/PRO Main study parameters/endpoints: 1. Primary endpoint is device success at 30 days Defined by * Absence of procedural mortality AND * Correct positioning of a single prosthetic heart valve into the proper anatomical location AND * Intended performance of the prosthetic heart valve (no severe prosthesis- patient mismatch and mean aortic valve gradient \< 20 mmHg or peak velocity \< 3 m/s, AND no moderate or severe prosthetic valve regurgitation). Severe prosthesis patient mismatch is defined by effective orifice area (EOAi) ≤0.65 cm2/m2 2. Safety endpoint at 1 year defined by the composite of all-cause death, disabling stroke, rehospitalization for heart failure or valve related problems.
Recruiting1 award N/A3 criteria
More about John Webb, MD
Clinical Trial Related5 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments John Webb, MD has experience with
- ACURATE Neo2™ Transfemoral TAVR System
- Medtronic CoreValve TAVR System
- Edwards SAPIEN 3 TAVR System
- ACURATE Prime™ Transfemoral TAVR System XL
- Edwards EVOQUE Tricuspid Valve Replacement System
- Edwards PASCAL System
Breakdown of trials John Webb, MD has run
Heart Valve Disease
Aortic Valve Stenosis
Aortic Stenosis
Tricuspid Regurgitation
Tricuspid Valve Regurgitation
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does John Webb, MD specialize in?
John Webb, MD focuses on Heart Valve Disease and Aortic Valve Stenosis. In particular, much of their work with Heart Valve Disease has involved treating patients, or patients who are undergoing treatment.
Is John Webb, MD currently recruiting for clinical trials?
Yes, John Webb, MD is currently recruiting for 2 clinical trials in Vancouver British Columbia. If you're interested in participating, you should apply.
Are there any treatments that John Webb, MD has studied deeply?
Yes, John Webb, MD has studied treatments such as ACURATE neo2™ Transfemoral TAVR System, Medtronic CoreValve TAVR System, Edwards SAPIEN 3 TAVR System.
What is the best way to schedule an appointment with John Webb, MD?
Apply for one of the trials that John Webb, MD is conducting.
What is the office address of John Webb, MD?
The office of John Webb, MD is located at: Providence Health - St. Paul's Hospital, Vancouver, British Columbia V6Z 1Y6 Canada. This is the address for their practice at the Providence Health - St. Paul's Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.